metformin and imeglimin

metformin has been researched along with imeglimin in 14 studies

Research

Studies (14)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (21.43)24.3611
2020's11 (78.57)2.80

Authors

AuthorsStudies
Fouqueray, P; Lebovitz, H; Pirags, V1
Bailey, CJ; Diamant, M; Fouqueray, P; Inzucchi, SE; Lebovitz, HE; Pirags, V; Schernthaner, G1
Brown, C; Chastain, LM; Maggu, GA; Vuylsteke, V1
Fraser-Spears, R; Kim, SS; La-Viola, B; Ramsinghani, S; Sikazwe, D; Witte, AP; Yendapally, R1
Bolze, S; Fouqueray, P; Perrimond-Dauchy, S1
Borel, AL; Cottet-Rousselle, C; Fontaine, E; Hallakou-Bozec, S; Lamarche, F; Vial, G1
Bolze, S; Fontaine, E; Fouqueray, P; Hallakou-Bozec, S; Moller, DE; Monternier, PA; Theurey, P; Vial, G1
Arapieva, AM; Bobrik, AG; Bobrik, DV; Khamitova, AD; Kuznetsov, KO; Mahmutova, EI; Nagaev, IR; Saetova, AA1
Atsumi, T; Cho, KY; Kameda, H; Kurihara, H; Miya, A; Miyoshi, H; Nagai, S; Nakamura, A; Nomoto, H; Takahashi, A; Takeuchi, J; Taneda, S1
Hozumi, K; Ishihara, N; Ishihara, T; Ogawa, W; Sugawara, K1
Atsumi, T; Fujitani, Y; Fukunaka, A; Fukushima, S; Inoue, R; Ito, S; Kyohara, M; Nishiyama, K; Okuyama, T; Ono, M; Sakai, C; Sato, A; Shirakawa, J; Terauchi, Y; Togashi, Y; Tsuno, T; Tsurumoto, A1
Ishioh, M; Miyagishi, S; Nozu, T; Okumura, T; Takakusaki, K1
Rachdaoui, N1
Abe, J; Ando, H; Fujiwara, H; Fujiwara, T; Jing, Z; Maida, Y; Mieda, M; Miura, K; Miyazaki, R; Morishige, JI; Nagata, N; Ono, M; Sakane, N; Shi, Y; Xu, P1

Reviews

2 review(s) available for metformin and imeglimin

ArticleYear
Imeglimin: A Potential New Multi-Target Drug for Type 2 Diabetes.
    Drugs in R&D, 2015, Volume: 15, Issue:3

    Topics: Apoptosis; Blood Glucose; Diabetes Mellitus, Type 2; Gluconeogenesis; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Metformin; Sitagliptin Phosphate; Triazines

2015
A review of phenformin, metformin, and imeglimin.
    Drug development research, 2020, Volume: 81, Issue:4

    Topics: Acidosis, Lactic; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Phenformin; Triazines

2020

Trials

4 trial(s) available for metformin and imeglimin

ArticleYear
Imeglimin, a novel glimin oral antidiabetic, exhibits a good efficacy and safety profile in type 2 diabetic patients.
    Diabetes, obesity & metabolism, 2012, Volume: 14, Issue:9

    Topics: Administration, Oral; Adolescent; Adult; Aged; Area Under Curve; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Treatment Outcome; Triazines; Young Adult

2012
The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy.
    Diabetes care, 2013, Volume: 36, Issue:3

    Topics: Adolescent; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome; Triazines; Young Adult

2013
Imeglimin Does Not Induce Clinically Relevant Pharmacokinetic Interactions When Combined with Either Metformin or Sitagliptin in Healthy Subjects.
    Clinical pharmacokinetics, 2020, Volume: 59, Issue:10

    Topics: Area Under Curve; Healthy Volunteers; Humans; Hypoglycemic Agents; Male; Metformin; Sitagliptin Phosphate; Triazines

2020
Add-on imeglimin versus metformin dose escalation regarding glycemic control in patients with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor plus low-dose metformin: study protocol for a multicenter, prospective, randomized, open-label, p
    BMJ open diabetes research & care, 2022, Volume: 10, Issue:6

    Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Drug Therapy, Combination; Glycated Hemoglobin; Glycemic Control; Humans; Hypoglycemic Agents; Metformin; Multicenter Studies as Topic; Prospective Studies; Randomized Controlled Trials as Topic; Treatment Outcome

2022

Other Studies

8 other study(ies) available for metformin and imeglimin

ArticleYear
The mechanism by which imeglimin inhibits gluconeogenesis in rat liver cells.
    Endocrinology, diabetes & metabolism, 2021, Volume: 4, Issue:2

    Topics: Adenosine Diphosphate; Adenosine Triphosphatases; Adenosine Triphosphate; Animals; Cells, Cultured; Gluconeogenesis; Hepatocytes; Hypoglycemic Agents; Male; Membrane Potential, Mitochondrial; Metformin; Mitochondria, Liver; Oxidation-Reduction; Oxygen Consumption; Rats, Wistar; Triazines

2021
Reduced lactic acidosis risk with Imeglimin: Comparison with Metformin.
    Physiological reports, 2022, Volume: 10, Issue:5

    Topics: Acidosis, Lactic; Animals; Diabetes Mellitus, Type 2; Dogs; Humans; Hypoglycemic Agents; Lactic Acid; Metformin; Mice; Rats; Renal Insufficiency; Triazines

2022
[Imeglimin: features of the mechanism of action and potential benefits].
    Problemy endokrinologii, 2022, 03-11, Volume: 68, Issue:3

    Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Metformin; Sitagliptin Phosphate; Triazines

2022
Effects of imeglimin on mitochondrial function, AMPK activity, and gene expression in hepatocytes.
    Scientific reports, 2023, 01-13, Volume: 13, Issue:1

    Topics: AMP-Activated Protein Kinases; Animals; Gene Expression; Hep G2 Cells; Hepatocytes; Humans; Hypoglycemic Agents; Metformin; Mice; Mitochondria

2023
Protective Effects of Imeglimin and Metformin Combination Therapy on β-Cells in db/db Male Mice.
    Endocrinology, 2023, 06-26, Volume: 164, Issue:8

    Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Glucose; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Male; Metformin; Mice; Mice, Inbred Strains

2023
Imeglimin prevents visceral hypersensitivity and colonic hyperpermeability in irritable bowel syndrome rat model.
    Journal of pharmacological sciences, 2023, Volume: 153, Issue:1

    Topics: Animals; Colon; Corticotropin-Releasing Hormone; Irritable Bowel Syndrome; Metformin; Rats

2023
Early Combination Therapies for the Preservation of Pancreatic β Cells in Type 2 Diabetes Mellitus.
    Endocrinology, 2023, 08-28, Volume: 164, Issue:10

    Topics: Animals; Diabetes Mellitus, Type 2; Insulin-Secreting Cells; Male; Metformin; Mice; Triazines

2023
Imeglimin profoundly affects the circadian clock in mouse embryonic fibroblasts.
    Journal of pharmacological sciences, 2023, Volume: 153, Issue:4

    Topics: Animals; ARNTL Transcription Factors; Circadian Clocks; Circadian Rhythm; Fibroblasts; Metformin; Mice; Rats; RNA, Messenger

2023